

Raltegravir Pediatric Granules Formulation

Version 7.1 Revision Date: 26.09.2023 SDS Number: 20458-00023 Date of last issue: 20.03.2023
Date of first issue: 09.10.2014

Section 1: Identification

Product name : Raltegravir Pediatric Granules Formulation

Manufacturer or supplier's details

Company : MSD

Address : 33 Whakatiki Street - Private Bag 908
Upper Hutt - New Zealand

Telephone : +1-908-740-4000

Emergency telephone number : +1-908-423-6000

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

Restrictions on use : Not applicable

Section 2: Hazard identification**GHS Classification**

Serious eye damage/eye irritation : Category 1

Reproductive toxicity : Category 2

Specific target organ toxicity - single exposure : Category 3

GHS label elements

Hazard pictograms :



Signal word : Danger

Hazard statements : H318 Causes serious eye damage.
H335 May cause respiratory irritation.
H361d Suspected of damaging the unborn child.

Precautionary statements : **Prevention:**
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read

Raltegravir Pediatric Granules Formulation

| | | | |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 20.03.2023 |
| 7.1 | 26.09.2023 | 20458-00023 | Date of first issue: 09.10.2014 |

and understood.

P261 Avoid breathing dust.

P271 Use only outdoors or in a well-ventilated area.

P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P304 + P340 + P312 IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER/ doctor if you feel unwell.

P305 + P351 + P338 + P310 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Immediately call a POISON CENTER/ doctor.

P308 + P313 IF exposed or concerned: Get medical advice/ attention.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

Section 3: Composition/information on ingredients

Substance / Mixture : Mixture

Components

| Chemical name | CAS-No. | Concentration (% w/w) |
|--------------------|-------------|-----------------------|
| Raltegravir | 871038-72-1 | >= 20 -< 30 |
| Cellulose | 9004-34-6 | >= 20 -< 30 |
| Magnesium stearate | 557-04-0 | >= 1 -< 10 |
| Ammonium hydroxide | 1336-21-6 | >= 0.1 -< 0.25 |

Section 4: First-aid measures

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.

Raltegravir Pediatric Granules Formulation

| | | | |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 20.03.2023 |
| 7.1 | 26.09.2023 | 20458-00023 | Date of first issue: 09.10.2014 |

| | | |
|---|---|--|
| | | Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse. |
| In case of eye contact | : | In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. If easy to do, remove contact lens, if worn. Get medical attention immediately. |
| If swallowed | : | If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water. |
| Most important symptoms and effects, both acute and delayed | : | Causes serious eye damage. May cause respiratory irritation. Suspected of damaging the unborn child. Contact with dust can cause mechanical irritation or drying of the skin. |
| Protection of first-aiders | : | First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8). |
| Notes to physician | : | Treat symptomatically and supportively. |

Section 5: Fire-fighting measures

| | | |
|---|---|---|
| Suitable extinguishing media | : | Water spray Alcohol-resistant foam Carbon dioxide (CO ₂) Dry chemical |
| Unsuitable extinguishing media | : | None known. |
| Specific hazards during fire-fighting | : | Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health. |
| Hazardous combustion products | : | Carbon oxides Nitrogen oxides (NO _x) Fluorine compounds Metal oxides |
| Specific extinguishing methods | : | Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area. |
| Special protective equipment for firefighters | : | In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment. |

Section 6: Accidental release measures

| | | |
|---|---|--|
| Personal precautions, protective equipment and emergency procedures | : | Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8). |
|---|---|--|

Raltegravir Pediatric Granules Formulation

| | | | |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 20.03.2023 |
| 7.1 | 26.09.2023 | 20458-00023 | Date of first issue: 09.10.2014 |

- Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Surround spill with absorbents and place a damp covering over the area to minimise entry of the material into the air.
Add excess liquid to allow the material to enter into solution.
Soak up with inert absorbent material.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

Section 7: Handling and storage

- Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
- Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.
- Advice on safe handling : Avoid breathing dust.
Do not swallow.
Do not get in eyes.
Avoid prolonged or repeated contact with skin.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Already sensitised individuals, and those susceptible to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respiratory irritants or sensitisers.
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Take care to prevent spills, waste and minimize release to the environment.
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working

Raltegravir Pediatric Granules Formulation

Version 7.1 Revision Date: 26.09.2023 SDS Number: 20458-00023 Date of last issue: 20.03.2023
 Date of first issue: 09.10.2014

place.
 When using do not eat, drink or smoke.
 Wash contaminated clothing before re-use.

Conditions for safe storage : Keep in properly labelled containers.
 Store locked up.
 Keep tightly closed.
 Keep in a cool, well-ventilated place.

Materials to avoid : Store in accordance with the particular national regulations.
 Do not store with the following product types:
 Strong oxidizing agents

Section 8: Exposure controls/personal protection

Components with workplace control parameters

| Components | CAS-No. | Value type (Form of exposure) | Control parameters / Permissible concentration | Basis |
|--------------------|-------------|-------------------------------------|--|----------|
| Raltegravir | 871038-72-1 | TWA | 1000 µg/m ³ (OEB 1) | Internal |
| Cellulose | 9004-34-6 | WES-TWA | 10 mg/m ³ | NZ OEL |
| | | TWA | 10 mg/m ³ | ACGIH |
| Magnesium stearate | 557-04-0 | WES-TWA | 10 mg/m ³ | NZ OEL |
| | | TWA (Inhalable particulate matter) | 10 mg/m ³ | ACGIH |
| | | TWA (Respirable particulate matter) | 3 mg/m ³ | ACGIH |
| Ammonium hydroxide | 1336-21-6 | TWA | 25 ppm (Ammonia) | ACGIH |
| | | STEL | 35 ppm (Ammonia) | ACGIH |

Engineering measures : Minimize workplace exposure concentrations.
 Apply measures to prevent dust explosions.
 Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).
 If sufficient ventilation is unavailable, use with local exhaust ventilation.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection

Raltegravir Pediatric Granules Formulation

| | | | |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 20.03.2023 |
| 7.1 | 26.09.2023 | 20458-00023 | Date of first issue: 09.10.2014 |

| | | |
|--------------------------|---|---|
| Material | : | Chemical-resistant gloves |
| Remarks | : | Choose gloves to protect hands against chemicals depending on the concentration and quantity of the hazardous substance and specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday. |
| Eye protection | : | Wear the following personal protective equipment: Chemical resistant goggles must be worn. If splashes are likely to occur, wear: Face-shield |
| Skin and body protection | : | Select appropriate protective clothing based on chemical resistance data and an assessment of the local exposure potential. Skin contact must be avoided by using impervious protective clothing (gloves, aprons, boots, etc). |

Section 9: Physical and chemical properties

| | | |
|--|---|---|
| Appearance | : | powder |
| Colour | : | off-white |
| Odour | : | odourless |
| Odour Threshold | : | No data available |
| pH | : | No data available |
| Melting point/freezing point | : | No data available |
| Initial boiling point and boiling range | : | No data available |
| Flash point | : | No data available |
| Evaporation rate | : | No data available |
| Flammability (solid, gas) | : | May form explosive dust-air mixture during processing, handling or other means. |
| Flammability (liquids) | : | No data available |
| Upper explosion limit / Upper flammability limit | : | No data available |
| Lower explosion limit / Lower flammability limit | : | No data available |
| Vapour pressure | : | No data available |

Raltegravir Pediatric Granules Formulation

| | | | |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 20.03.2023 |
| 7.1 | 26.09.2023 | 20458-00023 | Date of first issue: 09.10.2014 |

| | | |
|--|---|--|
| Relative vapour density | : | No data available |
| Relative density | : | No data available |
| Solubility(ies) Water solubility | : | No data available |
| Partition coefficient: n- octanol/water | : | No data available |
| Auto-ignition temperature | : | No data available |
| Decomposition temperature | : | No data available |
| Viscosity Viscosity, kinematic | : | No data available |
| Explosive properties | : | Not explosive |
| Oxidizing properties | : | The substance or mixture is not classified as oxidizing. |
| Molecular weight | : | No data available |
| Particle size | : | No data available |

Section 10: Stability and reactivity

| | | |
|------------------------------------|---|--|
| Reactivity | : | Not classified as a reactivity hazard. |
| Chemical stability | : | Stable under normal conditions. |
| Possibility of hazardous reactions | : | May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents. |
| Conditions to avoid | : | Heat, flames and sparks. Avoid dust formation. |
| Incompatible materials | : | Oxidizing agents |
| Hazardous decomposition products | : | No hazardous decomposition products are known. |

Section 11: Toxicological information

| | | |
|-----------------|---|--|
| Exposure routes | : | Inhalation Skin contact Ingestion Eye contact |
|-----------------|---|--|

Acute toxicity

Not classified based on available information.

Raltegravir Pediatric Granules Formulation

Version 7.1 Revision Date: 26.09.2023 SDS Number: 20458-00023 Date of last issue: 20.03.2023
Date of first issue: 09.10.2014

Components:**Raltegravir:**

Acute oral toxicity : LD50 (Mouse, male and female): > 2,000 mg/kg

Cellulose:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Magnesium stearate:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg
Method: OECD Test Guideline 423
Assessment: The substance or mixture has no acute oral toxicity
Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg
Remarks: Based on data from similar materials

Ammonium hydroxide:

Acute oral toxicity : LD50 (Rat): 350 mg/kg

Acute inhalation toxicity : Assessment: Corrosive to the respiratory tract.

Skin corrosion/irritation

Not classified based on available information.

Components:**Raltegravir:**

Species : Rabbit
Result : No skin irritation

Magnesium stearate:

Species : Rabbit
Result : No skin irritation
Remarks : Based on data from similar materials

Ammonium hydroxide:

Species : Rabbit
Result : Corrosive after 3 minutes to 1 hour of exposure
Remarks : Based on national or regional regulation.

Raltegravir Pediatric Granules Formulation

Version 7.1 Revision Date: 26.09.2023 SDS Number: 20458-00023 Date of last issue: 20.03.2023
Date of first issue: 09.10.2014

Serious eye damage/eye irritation

Causes serious eye damage.

Components:**Raltegravir:**

Species : Bovine cornea
Result : Severe irritation

Magnesium stearate:

Species : Rabbit
Result : No eye irritation
Remarks : Based on data from similar materials

Ammonium hydroxide:

Result : Irreversible effects on the eye
Remarks : Based on skin corrosivity.

Respiratory or skin sensitisation**Skin sensitisation**

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:**Raltegravir:**

Test Type : Local lymph node assay (LLNA)
Species : Mouse
Result : negative

Magnesium stearate:

Test Type : Maximisation Test
Exposure routes : Skin contact
Species : Guinea pig
Method : OECD Test Guideline 406
Result : negative
Remarks : Based on data from similar materials

Chronic toxicity**Germ cell mutagenicity**

Not classified based on available information.

Components:**Raltegravir:**

Genotoxicity in vitro : Test Type: reverse mutation assay

Raltegravir Pediatric Granules Formulation

| | | | |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 20.03.2023 |
| 7.1 | 26.09.2023 | 20458-00023 | Date of first issue: 09.10.2014 |

Result: negative

Test Type: Alkaline elution assay
 Test system: rat hepatocytes
 Result: negative

Test Type: Chromosomal aberration
 Method: OECD Test Guideline 473
 Result: negative

Genotoxicity in vivo : Test Type: In vivo micronucleus test
 Species: Mouse
 Result: negative

Test Type: Chromosomal aberration
 Method: OECD Test Guideline 475
 Result: negative

Cellulose:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
 Result: negative

Test Type: In vitro mammalian cell gene mutation test
 Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo
 cytogenetic assay)
 Species: Mouse
 Application Route: Ingestion
 Result: negative

Magnesium stearate:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test
 Result: negative
 Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro
 Method: OECD Test Guideline 473
 Result: negative
 Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)
 Result: negative
 Remarks: Based on data from similar materials

Ammonium hydroxide:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
 Result: negative

Raltegravir Pediatric Granules Formulation

| | | | |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 20.03.2023 |
| 7.1 | 26.09.2023 | 20458-00023 | Date of first issue: 09.10.2014 |

Carcinogenicity

Not classified based on available information.

Components:

Raltegravir:

Species : Mouse, male and female
 Exposure time : 104 weeks
 Result : negative

Cellulose:

Species : Rat
 Application Route : Ingestion
 Exposure time : 72 weeks
 Result : negative

Reproductive toxicity

Suspected of damaging the unborn child.

Components:

Raltegravir:

Effects on fertility : Test Type: Fertility/early embryonic development
 Species: Rat, male and female
 Application Route: Oral
 General Toxicity - Parent: NOAEL: 600 mg/kg body weight
 Result: negative

Effects on foetal development : Species: Rat
 Application Route: Oral
 General Toxicity Maternal: NOAEL: \geq 600 mg/kg body weight
 Teratogenicity: LOAEL F1: 300 mg/kg body weight
 Symptoms: Skeletal malformations
 Result: positive

Species: Rabbit
 General Toxicity Maternal: NOAEL: \geq 1,000 mg/kg body weight
 Teratogenicity: NOAEL: \geq 1,000 mg/kg body weight
 Result: negative

Reproductive toxicity - Assessment : Some evidence of adverse effects on development, based on animal experiments.

Cellulose:

Effects on fertility : Test Type: One-generation reproduction toxicity study
 Species: Rat
 Application Route: Ingestion
 Result: negative

Effects on foetal development : Test Type: Fertility/early embryonic development

Raltegravir Pediatric Granules Formulation

| | | | |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 20.03.2023 |
| 7.1 | 26.09.2023 | 20458-00023 | Date of first issue: 09.10.2014 |

ment

Species: Rat
Application Route: Ingestion
Result: negative

Magnesium stearate:

Effects on fertility : Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 422
Result: negative
Remarks: Based on data from similar materials

Effects on foetal development : Test Type: Embryo-foetal development
Species: Rat
Application Route: Ingestion
Result: negative
Remarks: Based on data from similar materials

STOT - single exposure

May cause respiratory irritation.

Components:

Raltegravir:

Exposure routes : Inhalation
Target Organs : Respiratory Tract
Assessment : May cause respiratory irritation.

STOT - repeated exposure

Not classified based on available information.

Repeated dose toxicity

Components:

Raltegravir:

Species : Dog
NOAEL : 90 mg/kg
Application Route : Oral
Exposure time : 371 d
Symptoms : Vomiting

Species : Rat
NOAEL : 30 mg/kg
LOAEL : 120 mg/kg
Application Route : Oral
Exposure time : 189 d
Target Organs : Stomach

Species : Mouse

Raltegravir Pediatric Granules Formulation

| | | | |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 20.03.2023 |
| 7.1 | 26.09.2023 | 20458-00023 | Date of first issue: 09.10.2014 |

NOAEL : 50 mg/kg
 LOAEL : 500 mg/kg
 Application Route : Oral
 Exposure time : 14 Weeks
 Target Organs : Stomach

Species : Rat
 NOAEL : 50 mg/kg
 LOAEL : 200 mg/kg
 Application Route : Oral
 Exposure time : 8 Weeks
 Target Organs : Stomach

Cellulose:

Species : Rat
 NOAEL : $\geq 9,000$ mg/kg
 Application Route : Ingestion
 Exposure time : 90 Days

Magnesium stearate:

Species : Rat
 NOAEL : > 100 mg/kg
 Application Route : Ingestion
 Exposure time : 90 Days
 Remarks : Based on data from similar materials

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Raltegravir:

Ingestion : Symptoms: Nausea, Diarrhoea, Headache, Fever, Rash, Skin irritation

Section 12: Ecological information

Ecotoxicity

Components:

Raltegravir:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l
 Exposure time: 96 h
 Method: OECD Test Guideline 203

LC50 (Cyprinodon variegatus (sheepshead minnow)): > 100 mg/l
 Exposure time: 96 h

Raltegravir Pediatric Granules Formulation

| | | | |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 20.03.2023 |
| 7.1 | 26.09.2023 | 20458-00023 | Date of first issue: 09.10.2014 |

- Method: OECD Test Guideline 203
- Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 100 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202
- Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): 66 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 201
- NOEC (Pseudokirchneriella subcapitata (green algae)): 3.8 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 201
- Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 9.3 mg/l
Exposure time: 33 d
Method: OECD Test Guideline 210
- Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 9.5 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211
- Toxicity to microorganisms : EC50: > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209
- NOEC: 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209
- Cellulose:**
- Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l
Exposure time: 48 h
Remarks: Based on data from similar materials
- Magnesium stearate:**
- Toxicity to fish : LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l
Exposure time: 48 h
Method: DIN 38412
Remarks: Based on data from similar materials
- Toxicity to daphnia and other aquatic invertebrates : EL50 (Daphnia magna (Water flea)): > 1 mg/l
Exposure time: 47 h
Test substance: Water Accommodated Fraction
Method: Directive 67/548/EEC, Annex V, C.2.
Remarks: Based on data from similar materials
No toxicity at the limit of solubility

Raltegravir Pediatric Granules Formulation

| | | | |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 20.03.2023 |
| 7.1 | 26.09.2023 | 20458-00023 | Date of first issue: 09.10.2014 |

Toxicity to algae/aquatic plants : EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l
Exposure time: 72 h
Test substance: Water Accommodated Fraction
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials
No toxicity at the limit of solubility

NOELR (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l
Exposure time: 72 h
Test substance: Water Accommodated Fraction
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials

Toxicity to microorganisms : EC10 (Pseudomonas putida): > 100 mg/l
Exposure time: 16 h
Test substance: Water Accommodated Fraction
Remarks: Based on data from similar materials

Ammonium hydroxide:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 0.89 mg/l
Exposure time: 96 h
Test substance: Neutralised product

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 101 mg/l
Exposure time: 48 h

M-Factor (Acute aquatic toxicity) : 1

Toxicity to fish (Chronic toxicity) : NOEC (Oncorhynchus mykiss (rainbow trout)): 0.0135 mg/l
Exposure time: 73 d
Test substance: Neutralised product

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 0.961 mg/l
Exposure time: 21 d
Remarks: Based on data from similar materials

Persistence and degradability**Components:****Raltegravir:**

Biodegradability : Result: rapidly degradable
Biodegradation: 50 %
Exposure time: 9 d
Method: OECD Test Guideline 302B

Stability in water : Hydrolysis: < 10 % (5 d)
Method: OECD Test Guideline 111

Raltegravir Pediatric Granules Formulation

| | | | |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 20.03.2023 |
| 7.1 | 26.09.2023 | 20458-00023 | Date of first issue: 09.10.2014 |

Cellulose:

Biodegradability : Result: Readily biodegradable.

Magnesium stearate:Biodegradability : Result: Not biodegradable
Remarks: Based on data from similar materials**Bioaccumulative potential****Components:****Raltegravir:**

Partition coefficient: n-octanol/water : log Pow: -0.328

Magnesium stearate:

Partition coefficient: n-octanol/water : log Pow: > 4

Mobility in soil

No data available

Other adverse effects

No data available

Section 13: Disposal considerations**Disposal methods**Waste from residues : Do not dispose of waste into sewer.
Dispose of in accordance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

Section 14: Transport information**International Regulations****UNRTDG**UN number : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable**IATA-DGR**UN/ID No. : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable

Raltegravir Pediatric Granules Formulation

| | | | |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 20.03.2023 |
| 7.1 | 26.09.2023 | 20458-00023 | Date of first issue: 09.10.2014 |

Packing group : Not applicable
 Labels : Not applicable
 Packing instruction (cargo aircraft) : Not applicable
 Packing instruction (passenger aircraft) : Not applicable

IMDG-Code

UN number : Not applicable
 Proper shipping name : Not applicable
 Class : Not applicable
 Subsidiary risk : Not applicable
 Packing group : Not applicable
 Labels : Not applicable
 EmS Code : Not applicable
 Marine pollutant : Not applicable

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

National Regulations

NZS 5433

UN number : Not applicable
 Proper shipping name : Not applicable
 Class : Not applicable
 Subsidiary risk : Not applicable
 Packing group : Not applicable
 Labels : Not applicable
 Hazchem Code : Not applicable

Special precautions for user

Not applicable

Section 15: Regulatory information

Safety, health and environmental regulations/legislation specific for the substance or mixture

HSNO Approval Number

HSR100425 Pharmaceutical Active Ingredients Group Standard

HSW Controls

Certified handler certificate not required.

Tracking hazardous substance not required.

Refer to the Health and Safety at Work (Hazardous Substances) Regulations 2017, for further information.

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

Raltegravir Pediatric Granules Formulation

| | | | |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 20.03.2023 |
| 7.1 | 26.09.2023 | 20458-00023 | Date of first issue: 09.10.2014 |

IECSC : not determined

Section 16: Other information

Revision Date : 26.09.2023

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Date format : dd.mm.yyyy

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)
 NZ OEL : New Zealand. Workplace Exposure Standards for Atmospheric Contaminants

ACGIH / TWA : 8-hour, time-weighted average
 ACGIH / STEL : Short-term exposure limit
 NZ OEL / WES-TWA : Workplace Exposure Standard - Time Weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Raltegravir Pediatric Granules Formulation

| | | | |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 20.03.2023 |
| 7.1 | 26.09.2023 | 20458-00023 | Date of first issue: 09.10.2014 |

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NZ / EN